Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...

Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

Artificial intelligence stands out as a particularly promising solution to the challenges of improving health literacy.

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

Some prior research had shown that gene therapy would not lower the amount of time children spend on ventilator support.

Each Sunday we feature a highlight reel of various articles posted on our website that week. Some prior research had shown ...

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Lucy van de Wiel, PhD, discusses how infertility is defined as the inability to conceive after 12 months of regular ...